These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26437261)

  • 21. Bioreducible polymer-mediated delivery of oncolytic adenovirus can attenuate antiviral immune response and concurrently enhance the induction of antitumor immune response to effectively prevent metastasis.
    Kasala D; Lee SH; Hong J; Oh E; Yoon AR; Yun CO
    Biomater Sci; 2022 Jul; 10(15):4293-4308. PubMed ID: 35766864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
    Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions.
    Yoon AR; Hong J; Kim M; Yun CO
    Sci Rep; 2018 Feb; 8(1):2233. PubMed ID: 29396500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
    Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
    Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically.
    Yuan X; Zhang Q; Li Z; Zhang X; Bao S; Fan D; Ru Y; Dong S; Zhang Y; Zhang Y; Ye Z; Xiong D
    Cancer Lett; 2016 Oct; 381(1):85-95. PubMed ID: 27450327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
    Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using a magnetic field to redirect an oncolytic adenovirus complexed with iron oxide augments gene therapy efficacy.
    Choi JW; Park JW; Na Y; Jung SJ; Hwang JK; Choi D; Lee KG; Yun CO
    Biomaterials; 2015 Oct; 65():163-74. PubMed ID: 26164117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Smart Accumulating Dual-Targeting Lipid Envelopes Equipping Oncolytic Adenovirus for Enhancing Cancer Gene Therapeutic Efficacy.
    Zhao Y; Le TMD; Hong J; Jiao A; Yoon AR; Yun CO
    ACS Nano; 2024 Oct; 18(41):27869-27890. PubMed ID: 39356167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery.
    Kim HA; Nam K; Kim SW
    Biomaterials; 2014 Aug; 35(26):7543-52. PubMed ID: 24894645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus.
    Choi IK; Shin H; Oh E; Yoo JY; Hwang JK; Shin K; Yu DC; Yun CO
    Int J Cancer; 2015 Nov; 137(9):2253-69. PubMed ID: 25944623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained local delivery of oncolytic short hairpin RNA adenoviruses for treatment of head and neck cancer.
    Jung SH; Choi JW; Yun CO; Yhee JY; Price R; Kim SH; Kwon IC; Ghandehari H
    J Gene Med; 2014; 16(5-6):143-52. PubMed ID: 24962819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma.
    Yoon AR; Hong J; Li Y; Shin HC; Lee H; Kim HS; Yun CO
    Cancer Res; 2019 Sep; 79(17):4503-4514. PubMed ID: 31289131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.
    Hu H; Qiu Y; Guo M; Huang Y; Fang L; Peng Z; Ji W; Xu Y; Shen S; Yan Y; Huang X; Zheng J; Su C
    Oncotarget; 2015 Jan; 6(2):1079-89. PubMed ID: 25473902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR negative tumor model.
    Jung SJ; Kasala D; Choi JW; Lee SH; Hwang JK; Kim SW; Yun CO
    Biomacromolecules; 2015 Jan; 16(1):87-96. PubMed ID: 25400213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas.
    Kwon OJ; Kim PH; Huyn S; Wu L; Kim M; Yun CO
    Clin Cancer Res; 2010 Dec; 16(24):6071-82. PubMed ID: 21169258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration.
    Choi JW; Dayananda K; Jung SJ; Lee SH; Kim D; Hu J; Bae YH; Yun CO
    Acta Biomater; 2015 Dec; 28():86-98. PubMed ID: 26365317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin.
    Kim PH; Sohn JH; Choi JW; Jung Y; Kim SW; Haam S; Yun CO
    Biomaterials; 2011 Mar; 32(9):2314-26. PubMed ID: 21227505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus.
    Doronin K; Shashkova EV; May SM; Hofherr SE; Barry MA
    Hum Gene Ther; 2009 Sep; 20(9):975-88. PubMed ID: 19469693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.